Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
New study launched to examine effects of rheumatologic agent on bone health

New study launched to examine effects of rheumatologic agent on bone health

BWH bioengineers develop flare-responsive hydrogel to treat arthritis

BWH bioengineers develop flare-responsive hydrogel to treat arthritis

New low-cost microfluidic device brings single-cell technology to bedside

New low-cost microfluidic device brings single-cell technology to bedside

Psoriasis drug also effective at reducing aortic inflammation

Psoriasis drug also effective at reducing aortic inflammation

Researchers discover link between rheumatoid arthritis and bacteria in milk

Researchers discover link between rheumatoid arthritis and bacteria in milk

Researchers win $6.5 million NIH grant to personalize diagnosis and treatment of psoriasis

Researchers win $6.5 million NIH grant to personalize diagnosis and treatment of psoriasis

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

BSR and RCGP introduce joint project to improve care for people with inflammatory arthritis

BSR and RCGP introduce joint project to improve care for people with inflammatory arthritis

Researchers reveal immune machinery that goes awry to trigger neutrophilic dermatosis

Researchers reveal immune machinery that goes awry to trigger neutrophilic dermatosis

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

Psoriatic arthritis patients experience multiple symptoms that can make diagnosis difficult, survey reveals

Psoriatic arthritis patients experience multiple symptoms that can make diagnosis difficult, survey reveals

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Almirall launches ‘Not Today’ story to raise awareness about psoriasis

Almirall launches ‘Not Today’ story to raise awareness about psoriasis

FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

Penn State dermatologist clarifies common myths about psoriasis

Penn State dermatologist clarifies common myths about psoriasis

Research finding opens door to new treatment options for inflammatory rheumatism

Research finding opens door to new treatment options for inflammatory rheumatism

New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar